Three-year data reveals widening performance gaps among Canadian shopping centres as top-tier malls strengthen their ...
13h
Bristol-Myers Squibb: The Market Is Not Pricing The Growth Portfolio That Replaces The Patent Cliff
Bristol-Myers Squibb (BMY) looks undervalued at 8.9x forward P/E; see growth catalysts, FDA/Phase 3 timelines, and a $68 ...
UnitedHealth is positioned for a sharp re-rating after a 48% drawdown driven by Medicare Advantage margin compression. Learn ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results